middle.news
Imugene Accelerates Cancer Trials with FDA Fast Track and A$20M Funding Boost
5:20am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Imugene Accelerates Cancer Trials with FDA Fast Track and A$20M Funding Boost
5:20am on Monday 2nd of June, 2025 AEST
Key Points
Four complete responses in Phase 1b azer-cel trial for relapsed/refractory DLBCL
FDA grants Fast Track Designation to azer-cel, expediting development
First Australian patient dosed in azer-cel trial; dose escalation approved in onCARlytics Phase 1
Patent allowances secured in China, India, and Australia for key immunotherapies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE